Barclays Maintains Overweight Rating for Baxter Intl: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Barclays has reaffirmed its Overweight rating on Baxter Intl (NYSE:BAX) and increased its price target from $52.00 to $54.00. Baxter Intl's shares are currently trading at $39.55, and the new price target suggests a potential upside of 36.54%. Baxter, known for its medical instruments and supplies, acquired Hillrom in 2021, enhancing its hospital-focused offerings. The company plans to spin off its kidney failure treatment operations by mid-2024.
February 12, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays reaffirms Overweight rating on Baxter Intl, raising price target to $54, indicating a 36.54% potential upside from the current price of $39.55.
The reaffirmation of the Overweight rating and the increase in price target by Barclays are strong positive signals for Baxter Intl. The potential 36.54% upside reflects confidence in Baxter's strategic direction, including its acquisition of Hillrom and plans to spin off its kidney failure treatment operations. These moves are likely to be viewed positively by investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100